{"id":"aqii-1","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T02:28:55.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123116,"model":"claude-sonnet-4-5-20250929"},"description":"aQII-1 is an investigational therapeutic agent being developed by Seqirus, currently in Phase 2 clinical trials. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"aQII-1","genericName":"aQII-1","companyName":"Seqirus","companyId":"seqirus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"aQII-1 is an investigational antibody that targets the programmed cell death 1 ligand 1 (PD-L1) and is classified as an inhibitor. It is being studied in a Phase 2 clinical trial for the treatment of influenza.","enrichmentLevel":2,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}